ArticleClinical case reports2020

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy.

Francesco Paolo Tambaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.